Our data shows that although specific IRF1 polymorphisms associate with decreased susceptibility to HIV infection they show no effect on disease progression, either measured by HIV-1 RNA levels or the slopes of CD4 decline before treatment initiation. This evidence concerns the gene CD4 and HIV infectious disease.